An update of preimplantation genetic diagnosis in gene diseases, chromosomal translocation, and aneuploidy screening

Li-Jung Chang1*, Shee-Uan Chen1*, Yi-Yi Tsai1, Chia-Cheng Hung2,3, Mei-Ya Fang2, Yi-Ning Su1,2,3, Yu-Shih Yang1

1Departments of Obstetrics and Gynecology, 2Medical Genetics, 3Graduate Institute of Clinical Genomics, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan

Preimplantation genetic diagnosis (PGD) is gradually widely used in prevention of gene diseases and chromosomal abnormalities. Much improvement has been achieved in biopsy technique and molecular diagnosis. Blastocyst biopsy can increase diagnostic accuracy and reduce allele dropout. It is cost-effective and currently plays an important role. Whole genome amplification permits subsequent individual detection of multiple gene loci and screening all 23 pairs of chromosomes. For PGD of chromosomal translocation, fluorescence in-situ hybridization (FISH) is traditionally used, but with technical difficulty. Array comparative genomic hybridization (CGH) can detect translocation and 23 pairs of chromosomes that may replace FISH. Single nucleotide polymorphisms array with haplotyping can further distinguish between normal chromosomes and balanced translocation. PGD may shorten time to conceive and reduce miscarriage for patients with chromosomal translocation. PGD has a potential value for mitochondrial diseases. Preimplantation genetic haplotyping has been applied for unknown mutation sites of single gene disease. Preimplantation genetic screening (PGS) using limited FISH probes in the cleavage-stage embryo did not increase live birth rates for patients with advanced maternal age, unexplained recurrent abortions, and repeated implantation failure. Polar body and blastocyst biopsy may circumvent the problem of mosaicism. PGS using blastocyst biopsy and array CGH is encouraging and merit further studies. Cryopreservation of biopsied blastocysts instead of fresh transfer permits sufficient time for transportation and genetic analysis. Cryopreservation of embryos may avoid ovarian hyperstimulation syndrome and possible suboptimal endometrium.

Keywords: Array Comparative Genomic Hybridization; Preimplantation Genetic Diagnosis; Preimplantation Genetic Screening; Single Nucleotide Polymorphisms Array; Vitrification; Whole Genome Amplification; Human

Introduction

Preimplantation genetic diagnosis (PGD) was first successfully performed in humans for prevention of X-linked disease in 1990 [1]. It gains a gradually important role in the prevention for Mendelian hereditary diseases and unbalanced chromosomal translocation. PGD provides an alternative of prenatal diagnosis with selective termination of pregnancy for couples accompanying a high risk of affected offspring. More indications have been applied as aneuploidy screening, human leukocyte antigen (HLA) typing, adult-onset Mendelian diseases, cancer predisposition syndromes and mitochondrial diseases [2,3]. Significant advancement has been attained in biopsy technique and molecular diagnosis. Vitrification of embryo after blastocyst biopsy permits sufficient time for shipment of specimen and diagnosis in the orderly fashion [4]. In this update, we will review indications, present approaches to retrieve cells for PGD, diagnostic...
technology, accuracy and possible misdiagnosis in details.

PGD for single gene disease and three different biopsy approaches

In principle, all monogenic disorders for which prenatal diagnosis is available can be examined by PGD as well. Many diseases have been successfully applied including thalassemia, cystic fibrosis, hemophilia, spinal muscular atrophy, neurofibromatosis, and congenital deafness, etc. [1-7]. There are three potential sources of embryonic genetic material for PGD, including polar bodies from oocytes, blastomeres from cleavage-stage embryos, and trophectoderm cells from blastocysts [8,9]. The polar bodies can be used for the indirect genetic analysis of the oocyte. The disadvantage is that it does not permit the analysis of the paternal genetic material. Since beginning, cleavage-stage biopsy with aspiration of one blastomere is the most common approach for PGD. In the recent years, blastocyst biopsy is gradually widely used. Both of them allow analysis of maternal and paternal origin.

PCR-based tests using single cell have possibility of ADO

Polymerase chain reaction (PCR) of single cells is vulnerable to contamination and allele dropout (ADO). ADO occurs when one of the two alleles fails to be amplified and only the other allele is amplified. In autosomal-dominant disorders, ADO of the affected allele might lead to the transfer of an affected embryo. For autosomal recessive conditions, ADO will not cause serious misdiagnosis [7], but the number of embryos available for transfer would reduce and this may result in a decreased pregnancy rate. The data of ADO in direct amplification of gene locus ranges from 5% to 33% [10,11]. The ADO rates in whole genome amplification (WGA) are from 5% to 31% [12,13], which are comparable to those obtained by direct amplification of gene locus. The incidence of ADO may depend on the cell number analyzed, the genes tested, and the lysis conditions, the PCR conditions, or the method of WGA [14]. To reduce the ADO rate below 10% would be imperative [15].

Polymorphic markers are helpful to find ADO that prevents misdiagnosis

Polymorphic markers with short tandem repeats (STR) or single nucleotide polymorphisms (SNP) close to the mutated gene have been used for linkage analysis to provide an additional confirmation of genotyping and an evidence of ADO [16,17]. STR markers also help to detect contamination of exogenous DNA with different STR sizes. Sufficient numbers (at least three) of linked markers are recommend-

ed to be tested together with the causative gene [15].

Blastocyst biopsy may increase diagnostic accuracy and reduce ADO. It is cost-effective and may replace cleavage-stage biopsy

Blastocyst biopsy providing more cells than the cleavage-stage biopsy (5-10 cells vs. 1-2 cells) for genetic analysis may potentially reduce the risk of amplification failure and ADO [18]. Kokkali et al. [18] prospectively compared genotyping success and implantation rates in PGD cycles after biopsy at the blastocyst versus the cleavage stage. They found that the genotyping success rate was significantly higher in the blastocyst group (94%) than in the cleavage-stage group (75%). The implantation and pregnancy rates were not statistically different. With the higher genotyping success rates, trophectoderm biopsy would be relatively cost-effective and less labor-intensive, because only embryos competently developing to the blastocyst stage are biopsied.

Blastocyst biopsy plus vitrification permits sufficient time for diagnosis, and may also avoid suboptimal endometrium

Embryo biopsy and fresh embryo transfer are traditionally performed in the PGD cycle. However, prior to embryo transfer, the time allowed for shipment of the specimens to the reference laboratory and performance of molecular diagnosis is limited, especially after blastocyst biopsy. Vitrification of blastocysts has been demonstrated to achieve high survival rate and pregnancy rate [19]. The strategy of PGD for monogenic diseases using blastocyst biopsy, vitrification, WGA accompanied by double confirmatory genotypings, and thawed embryo transfer have been successfully performed [4]. In addition, cryopreservation of embryos may be beneficial for patients of high responder to circumvent risk of ovarian hyperstimulation syndrome and possible suboptimal endometrium [20-22].

PGD for adult-onset autosomal diseases and cancer predisposition syndromes

PGD to exclude transmission of an autosomal dominant adult-onset disease would be more acceptable to at-risk families than the pregnancy termination after prenatal diagnosis. Huntington disease or other neurodegenerative diseases have been successfully applied [23]. PGD has also been performed for familial cancer syndromes including BRCA1, multiple endocrine neoplasia, familial adenomatous polyposis, Li-Fraumeni syndrome, retinoblastoma and von Hippel-Lin-
the high copy number of mtDNA makes the analysis feasible with
risk of disease for women with a high mutation load [31]. Technically,
low mutant load of embryos, PGD may be performed to reduce the
finite disease-free diagnosis can be achieved. However, by transferring
natal diagnosis, the value of PGD would be doubtful because no defi-
phenotype can not be accurately predicted. In this situation, like pre-
could transmit a various amount of mutation to her offspring. The
mitochondrial DNA (mtDNA) mutation could be heteroplasmic and
heredity of mitochondrial disease is uncertain. A woman carrying a
ease [2]. For the patients with unknown nuclear gene defects, the
PGD with HLA haplotyping and stem cell transplantation
In families having a diseased child with recessive genetic disorders
such as Fanconi anemia or thalassemia, the couple undergoing PGD
and HLA typing may not only avoid another genetically diseased
child but also have a HLA-compatible sibling of the diseased child.
The likelihood of a genetically normal and HLA-compatible embryo is
3 in 16. Therefore, perhaps several treatment cycles would be needed
before a pregnancy can be achieved. After birth of the neonate, um-
bilical cord blood can be collected and hematopoietic stem cell trans-
plantation can be applied to cure the diseased child [5,29]. The posi-
tive ethical background has been recently well discussed [30].
A potential, but uncertain, value of PGD for mitochondrial disease with unknown nuclear
gene defects
PGD provides a reasonable option for mitochondrial disease with
nuclear gene defects, like the treatment of autosomal recessive dis-
ease [2]. For the patients with unknown nuclear gene defects, the
heredity of mitochondrial disease is uncertain. A woman carrying a
mitochondrial DNA (mtDNA) mutation could be heteroplasmic and
could transmit a various amount of mutation to her offspring. The
phenotype can not be accurately predicted. In this situation, like pre-
natal diagnosis, the value of PGD would be doubtful because no defi-
nite disease-free diagnosis can be achieved. However, by transferring
low mutant load of embryos, PGD may be performed to reduce the
risk of disease for women with a high mutation load [31]. Technically,
the high copy number of mtDNA makes the analysis feasible with
less amplification failure and ADO [2]. But, the heteroplasmic charac-
teristics may raise a question concerning the representation of biop-
sied samples for the whole embryo. For embryo transfer, a cut-off
point should be set regarding the mutant load of embryos. Preferen-
tial transfer of male embryos with low mutant load could be a moral-
ly acceptable way of avoiding transgenerational risks [32].
WGA permits individual detection of multiple
gene loci and screening all 23 pairs of
chromosomes
Single cell or few cells obtained for PGD contains very limited DNA
material. In order to detect mutated gene and polymorphic markers,
multiplex PCR was traditionally used. It is critical to design compatible
multiple primer sequences and conditions when several PCR reactions
may interfere mutually in a tube. If one of the PCR reactions failed,
the detection procedures can not be repeated. The utilization of WGA
to produce a DNA library could provide sufficient DNA templates for
multiple independent examinations of gene mutations and polymor-
phic markers as well as repeating confirmations for an uncertain result.
Different genotyping methods can also be used for double confirma-
tions of diagnosis [4]. The WGA products also allow detecting chro-
osomal translocation and screening all 23 pairs of chromosomes.
A few WGA methods have been used in PGD [5,33]. Primer exten-
sion pre-amplification (PEP) using a random mixture of 15-base oli-
gonucleotides was estimated to amplify 91% genome of a cell. How-
ever, the microsatellite loci used for fingerprinting were not accurate-
lly amplified. OmniPlex converts randomly fragmented genomic DNA
into a library, and has an amplification of > 99.8% genome achieving
a SNP call rate of > 98%. MDA using bacteriophage Phi29 DNA poly-
merase and random hexamer primers is recently developed for WGA
with unbiased amplification [13,34]. MDA is a non-PCR-based meth-
od that may prevent generation of relatively short DNA fragments and
avoid possibility of mutation introduction [35]. A few clinical applica-
tions of MDA for PGD have been reported, such as for Marfan syn-
drome, Duchenne muscular dystrophy, cystic fibrosis, β-thalassemia,
and Huntington chorea, and neurofibromatosis type 1 [4]. The oth-
er WGA methods including linker adaptor and GenomePlex have
been investigated [35,36]. The advantages of each WGA method in
PGD deserve further studies.
PGD provides an alternative to achieve normal
pregnancy for patients with chromosomal translocation
It is estimated that 1 in 625 individuals carries a balanced chromo-
somal translocation. In couples with recurrent miscarriage, the inci-
dence of either of the couple being a carrier of a structural chromosome abnormality is approximately 4-5%, mainly including reciprocal translocations and Robertsonian translocations [37]. In the case of reciprocal translocation, at meiosis I during gametogenesis, the two pairs of homologous chromosomes associate at the pachytene stage to form a quadrivalent with matching of homologous segments. Several modes of segregation including 2:2 alternate, adjacent-1, adjacent-2, 3:1 and 4:0 may occur. At meiosis II, anaphase non-disjunction may also happen. The theoretical chance of producing normal or balanced gametes is 4 of 32 for reciprocal translocation, and it is 4 of 16 for Robertsonian translocations. However, the actual percentage depends on several factors, including which chromosomes involved, the breakpoints, and the sex of the carrier [38]. The carriers of balanced chromosomal translocation are at increased risk for infertility, pregnancy loss, and offspring with congenital abnormalities and mental retardation as a result of unbalanced segregation. PGD provides an option to exclude the unbalanced embryos.

FISH is traditionally used for PGD of chromosomal translocation, but with technical difficulty

Initial research of chromosomal translocation using Fluorescence in-situ hybridization (FISH) involved painting probes for metaphase chromosomes of polar bodies. A major shortcoming of this method is that only translocations of the female can be examined. Then, probes that spanned or flanked the translocation breakpoints were used for the interphase nucleus of a blastomere from cleavage-stage embryos. It can distinguish normal embryos from embryos of balanced and unbalanced translocation. But this methodology was restricted by the cost and the time needed to make specific probes. The subtelomere probes in combination with centromeric probes are commonly used that obviated the need for specific probe development for each rearrangement [38,39]. But this strategy will not differentiate between normal and balanced embryos. The FISH method is technically difficult on fixation of blastomeres. Several drawbacks may be encountered including hybridization failure, signal overlap, and splitting that can affect the accuracy of the interpretation [40]. FISH analysis may offer a positive predictive value of 83% and negative predictive value of 81% [41]. Wrong results may eliminate normal/balanced embryos for transfer, or lead to transfer of abnormal embryos.

PCR-based PGD for chromosomal translocation avoids difficulty of cell fixation

The PCR-based PGD protocol for translocations has the potential to overcome several inherent limitations of FISH-based tests [17]. They are not dependent on cell fixation onto a microscope slide, a critical step that requires skill and experience, with the potential to increase the percentage of embryos with a positive result. It is easier to train staff in, and monitor, the placing of single cells into PCR tubes than teaching the fixation. It has potential improvements in terms of test performance, automation, turnaround time, sensitivity, and reliability. Both FISH and PCR-based methods allow identification of aneuploidies simultaneously, but only for a limited number of chromosomes. The array comparative genomic hybridization (CGH) after WGA has the above advantages and can detect all 24 chromosomes.

Array CGH detects translocation and 23 pairs of chromosomes and may replace FISH for PGD of chromosomal translocation

Array CGH permits visualization of all 46 interphase chromosomes. The tested sample genome is first amplified through WGA and labeled with one color. The normal reference sample is also amplified and labeled with another color. These samples are used as probes to hybridize onto normal metaphase chromosomal plates. With image-processing software, unbalanced structural differences between the normal reference and test sample can be shown [42]. Array CGH provides the added benefit of simultaneous aneuploidy screening of all 24 chromosomes [43,44]. Another advantage of array CGH is that it does not require preclinical validation before each IVF cycle, which is required for FISH. This avoids postponement of IVF treatment. Fiorentino et al. [44] reported 28 cycles of PGD at the cleavage embryo for chromosomal translocations. A high percentage of embryos (93%) were successfully diagnosed. Embryos suitable for transfer were in 60% of started cycles. A 70% of pregnancy rate per transfer cycle was achieved. Array CGH merits further validation in the blastocyst biopsy.

SNP microarray can distinguish between normal chromosomes and balanced translocation

SNPs account for most gene variants found in humans and can be used as markers for genome-wide association study. SNP array analysis after WGA not only explores chromosomal aberrations but also provides information of haplotypes [45]. It can distinguish between normal and balanced chromosomes in embryos from translocation carriers. In addition, SNP array can also screen aneuploidy of all 24 chromosomes. Treff et al. [46] reported successful application of SNP array for PGD to distinguish between normal and balanced chromosomes in embryos from a translocation carrier. This may provide an important option for these patients to prevent their offspring from facing the same fertility problem.
For patients of balanced chromosomal translocation, the live birth rates are similar between PGD and natural conception

Franssen et al. [37] performed a systematic review and found that after natural conception, live birth rate per couple varied between 33 and 60% (median 55%). After PGD, live birth rate per couple varied between 0 and 100% (median 31%). It has been reported that 15-26% of the embryos were transferable in patients of reciprocal translocations, confirming the high level of chromosomally abnormal embryos [38]. This might explain why the results of PGD in some couples are relatively low [47]. Therefore, there are insufficient data indicating that PGD improves the live birth rate in couples with recurrent miscarriage carrying a structural chromosome abnormality.

PGD may shorten time to conceive and reduce miscarriage for patients of balanced chromosomal translocation

For patients with chromosomal translocation and repeated miscarriage, PGD may reduce time to get pregnancy. In the recent two reports, the cumulative pregnancy rate using PGD was 57-87%, involving an average of 1.2-1.4 cycles [48,49]. The short time (<4 months) undergoing PGD achieves pregnancy in contrast with the much longer interval (mean, 4-6 years) for natural conception. Pregnancy loss rate was significantly reduced to 13% post-PGD compared with 88.5% in previous non-PGD pregnancies. This is close to a sevenfold reduction in loss rate.

Costs and benefits of PGD in chromosomal translocation should be considered for each couple

PGD is an option when the couple with balanced translocation has also a fertility problem. For those couple without fertility difficulty, the costs and benefits should be considered in light of the limited change in live birth rate. PGD may shorten the time to achieve normal pregnancy and reduce miscarriage rate. The pregnancy rate is higher for selected patients with younger age and many good quality embryos available. But, the pregnancy rate would be lower for patient with older age and few embryos available. The possible treatment options should be provided and discussed with the couple.

The rationales of PGS for advanced maternal age, idiopathic repeated pregnancy loss, recurrent aneuploidy, or repeated implantation failure

Pregnancy rates and live birth rates decline with increasing maternal age. Miscarriage rates increases also. The primary reason is high embryonic loss due to aneuploidy. It has been found that 50% of morphologically normal embryos in women >35 years old are chromosomally abnormal [50]. More than 50% of first-trimester spontaneous abortions are chromosomal aneuploidy. Hence, it could be effective to increase live birth rates by performing PGS and transferring euploid embryos for patients of advanced maternal age, repeated implantation failure, and idiopathic recurrent pregnancy loss. It may be applied in single embryo transfer. It is supposed to improve implantation rates, reduce miscarriages and trisomic offspring, and ultimately lead to an increase in live birth rates [51,52]. However, aneuploidy is not the absolute cause of implantation failure or idiopathic recurrent pregnancy loss. The cost and benefits of PGS should be considered for individual patients.

PGS using limited FISH probes in the cleavage-stage embryos is not effective

Since the late 1990s, favorable ongoing pregnancy rates for advanced maternal age were achieved in initial studies using FISH-based PGS on cleavage-stage embryos [53]. However, the recent ten randomized controlled trials have shown that PGS does not increase live birth rates, although these studies are all confounded by limited power. Meta-analysis of these trials shows a statistically significant reduction of ongoing pregnancies after PGS (13% after PGS, vs. 21% in the control group) [53]. For unexplained recurrent miscarriage, there were no randomized controlled trials on this topic. A systematic review was to assess live birth rates and miscarriage rates after PGS or natural conception [54]. From the limited data, a similar live birth rate is reported for PGS and natural conception (35% and 42%, respectively). The miscarriage rate for the PGS group (9%) appears to be lower than in the natural conception group (28%). For repeated implantation failures, the existing data of PGS are also limited and inconsistent. Some studies are suggestive of increased pregnancy rates for younger women (average age, 30-33 years), while others did not verify any advantage [55]. Overall, the present data are not sufficient to support the use of PGS and FISH at the cleavage-stage embryos to improve the live birth rates in patients with advanced maternal age, recurrent pregnancy loss, or repeated implantation failure.

Polar body and blastocyst biopsy may circumvent the problem of mosaicism of the cleavage-stage embryo biopsy

Two major factors may explain the negative result of PGS and FISH on day 3 embryos, including chromosomal mosaicism and insufficient number of chromosomes tested [56]. The tested blastomere...
may not be representative for the whole embryo owing to mosaicism or the possibility of self-correction of aneuploidy within the embryo. As mosaicism is not present at the oocyte, it seems to be preferable to opt for polar body biopsy. The disadvantage of polar bodies is that only the maternal aneuploidies can be studied. However, the vast majority (more than 90%) of human aneuploidies is maternal origin. Testing the polar body is ethically acceptable in countries that do not allow testing of embryos. PGS at the blastocyst stages may provide more accurate information for chromosome abnormalities than at the cleavage stage. Although blastocysts may also display mosaicism, several cells can be biopsied at this stage that is more representative for the whole embryo [57].

PGS using blastocyst biopsy or polar body biopsy and array CGH may replace cleavage-stage biopsy and limited FISH assay

Initial results for patients of advanced maternal age with repeated implantation failure receiving blastocyst biopsy and array CGH for PGS were encouraging [56]. Fragouli et al. [56] found that implantation and pregnancy rates for the patients with polar body biopsy were 11% and 21%, respectively, whereas for patients receiving blastocyst biopsy they were 58% and 69%. Blastocyst analysis was associated with high pregnancy rates, suggesting that comprehensive chromosome screening may assist these patients in achieving pregnancies. Blastocyst or polar bodies biopsy using array CGH are recommended for randomized controlled trials for women of advanced maternal age, idiopathic recurrent abortions or repeated aneuploidy, and repeated implantation failure.

Misdiagnosis may occur in PGD and prenatal confirmation is recommended

Some misdiagnoses of PGD had been reported in the literature [9, 40]. The causes of misdiagnosis may include maternal or paternal contamination, ADO, and chromosomal mosaicism [40]. In face of the risk of misdiagnoses, prenatal diagnosis is recommended to confirm the PGD result when a pregnancy is achieved.

PGD babies do not increase for congenital abnormalities

There are some cohort studies concerning the pediatric follow-up of PGD babies. Liebaers et al. [58] reported a thorough, systematic study of PGD offspring judged on the basis of a physical examination 2 months after birth. Anomalies in PGD babies, compared to a previously reported cohort study of ICSI offspring, structural malforma-

Ethic aspect of PGD

PGD is gradually widely acceptable as an alternative to prevent the birth of a child with a hereditary disease including single gene disorder and chromosomal rearrangements. PGD for autosomal dominant late-onset disorders, cancer predisposition syndrome, PGD/HLA typing, and mtDNA mutations is more controversial. The experienced geneticist and infertility doctor should provide comprehensive counseling to the couple and explain the theoretical percentage of unaffected embryos. The severity of the disease, the age of onset of the disease, and the penetrance of the gene mutation are discussed. The odds of a misdiagnosis inherent to PCR or FISH are explained, and subsequent genotype confirmation of the pregnancy using conventional prenatal diagnosis is indicated. The cost, risk, and benefits should be well-explained. The decision would be determined by the couples.

Conclusion

PGD gains a gradually important role in the prevention of Mendelian hereditary diseases and unbalanced chromosomal translocation. More indications have been applied as aneuploidy screening, HLA typing, adult-onset autosomal disease, cancer predisposition syndrome and mitochondrial disease. Polymorphic markers are essential to find ADO that prevents misdiagnosis. Blastocyst biopsy increases diagnostic accuracy that may replace the cleavage-stage biopsy. PGD may shorten time to conceive and reduce miscarriage for patients with chromosomal translocation. PGS using blastocyst biopsy and array CGH is encouraging. Cryopreservation of biopsied blastocysts permits sufficient time for molecular diagnosis. That may also circumvent risk of ovarian hyperstimulation syndrome and possible suboptimal endometrium. Array CGH can detect translocation and 23 pairs of chromosomes and may replace FISH for PGD of chromosomal translocation and PGS. PGD can currently offer with a high accuracy of 95-99%, and may result in a pregnancy rate of 20-60%, depending on indications and age.

Conflict of interest

No potential conflict of interest relevant to this article was reported.
References

1. Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 1990;344:768-70.

2. Geraedts JP, De Wert GM. Preimplantation genetic diagnosis. Clin Genet 2009;76:315-25.

3. Simpson JL. Preimplantation genetic diagnosis at 20 years. Prenat Diagn 2010;30:682-95.

4. Chen YL, Hung CC, Lin SY, Fang MY, Tsai YY, Chang LJ, et al. Successful application of the strategy of blastocyst biopsy, vitrification, whole genome amplification, and thawed embryo transfer for preimplantation genetic diagnosis of neurofibromatosis type 1. Taiwan J Obstet Gynecol 2011;50:74-8.

5. Chen SU, Su YN, Fang MY, Chang LJ, Tsai YY, Lin LT, et al. PGD of beta-thalassaemia and HLA haplotypes using OmniPlex whole genome amplification. Reprod Biomed Online 2008;17:699-705.

6. Wu CC, Lin SY, Su YN, Fang MY, Chen SU, Hsu CJ. Preimplantation genetic diagnosis (embryo screening) for enlarged vestibular aqueduct due to SLC26A4 mutation. Audiol Neurootol 2010;15:311-7.

7. Hung CC, Chen SU, Lin SY, Fang MY, Chang LJ, Tsai YY, et al. Preimplantation genetic diagnosis of beta-thalassaemia using real-time polymerase chain reaction with fluorescence resonance energy transfer hybridization probes. Anal Biochem 2010;400:69-77.

8. Chen SU, Chao KH, Wu MY, Chen CD, Ho HN, Yang YS. The simplified two-pipette technique is more efficient than the conventional three-pipette method for blastomere biopsy in human embryos. Fertil Steril 1998;69:569-75.

9. Dreesen J, Drüseadu M, Smeets H, de Die-Smulders C, Coonen E, Dumoulin J, et al. Validation of preimplantation genetic diagnosis by PCR analysis: genotype comparison of the blastomere and corresponding embryo, implications for clinical practice. Mol Hum Reprod 2008;14:573-9.

10. Ray PF, Handyside AH. Increasing the denaturation temperature during the first cycles of amplification reduces allele dropout from single cells for preimplantation genetic diagnosis. Mol Hum Reprod 1996;2:213-8.

11. Piyamongkol W, Bermúdez MG, Harper JC, Wells D. Detailed investigation of factors influencing amplification efficiency and allele drop-out in single cell PCR: implications for preimplantation genetic diagnosis. Mol Hum Reprod 2003;9:411-20.

12. Renwick PJ, Lewis CM, Abbs S, Ogilvie CM. Determination of the genetic status of cleavage-stage human embryos by microsatellite marker analysis following multiple displacement amplification. Prenat Diagn 2007;27:206-15.

13. Glentis S, SenGupta S, Thornhill A, Wang R, Craft I, Harper JC. Molecular comparison of single cell MDA products derived from different cell types. Reprod Biomed Online 2009;19:89-98.

14. Sermon K, De Rycke M. Single cell polymerase chain reaction for preimplantation genetic diagnosis: methods, strategies, and limitations. Methods Mol Med 2007;132:31-42.

15. Preimplantation Genetic Diagnosis International Society (PGDIS). Guidelines for good practice in PGD: programme requirements and laboratory quality assurance. Reprod Biomed Online 2008;16:134-47.

16. Gutiérrez-Mateo C, Sánchez-García JF, Fischer J, Tormasi S, Cohen J, Munné S, et al. Preimplantation genetic diagnosis of single-gene disorders: experience with more than 200 cycles conducted by a reference laboratory in the United States. Fertil Steril 2009;92:1544-56.

17. Fiorentino F, Kokkali G, Bricick A, Stavrou D, Ismailoglu B, De Palma R, et al. Polymerase chain reaction-based detection of chromosomal imbalances on embryos: the evolution of preimplantation genetic diagnosis for chromosomal translocations. Fertil Steril 2010;94:2001-11.e6.

18. Kokkali G, Traeger-Synodinos J, Vrettou C, Stavrou D, Jones GM, Cram DS, et al. Blastocyst biopsy versus cleavage stage biopsy and blastocyst transfer for preimplantation genetic diagnosis of beta-thalassaemia: a pilot study. Hum Reprod 2007;22:1443-9.

19. Liebermann J. Vitrification of human blastocysts: an update. Reprod Biomed Online 2009;19 Suppl 4:4328.

20. Chen SU, Chen CD, Yang YS. Ovarian hyperstimulation syndrome (OHSS): new strategies of prevention and treatment. J Formos Med Assoc 2008;107:509-12.

21. Chen CD, Wu MY, Chao KH, Lien YR, Chen SU, Yang YS. Update on management of ovarian hyperstimulation syndrome. Taiwan J Obstet Gynecol 2011;50:2-10.

22. Liu Y, Lee KF, Ng EH, Yeung WS, Ho PC. Gene expression profiling of human peri-implantation endometria between natural and stimulated cycles. Fertil Steril 2008;90:2152-64.

23. Chow JF, Yeung WS, Lau EY, Lam ST, Tong T, Ng EH, et al. Singleton birth after preimplantation genetic diagnosis for Huntingdon disease using whole genome amplification. Fertil Steril 2009;2009;92:828.e7-10.

24. Rechitsky S, Verlinsky O, Chistokhina A, Sharapova T, Ozen S, Masciangelo C, et al. Preimplantation genetic diagnosis for single-gene disorders: experience with more than 200 cycles conducted by a reference laboratory in the United States. Fertil Steril 2009;92:1544-56.

25. Spits C, De Rycke M, Van Ranst N, Verpoest W, Lissens W, Van Steirteghem A, et al. Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenat Diagn 2007;27:447-56.

26. Lau EC, Janson MM, Roesler MR, Avner ED, Strawn EY, Bick DP. Birth of a healthy infant following preimplantation PKHD1 hap-
lotyping for autosomal recessive polycystic kidney disease using multiple displacement amplification. J Assist Reprod Genet 2010; 27:397-407.

27. Renwick P, Trussler J, Lashwood A, Braude P, Ogilvie CM. Preimplantation genetic haplotyping: 127 diagnostic cycles demonstrating a robust, efficient alternative to direct mutation testing on single cells. Reprod Biomed Online 2010;20:470-6.

28. Qubbaj W, Al-Swaid A, Al-Hassan S, Awartani K, Deek H, Coskun S. First successful application of preimplantation genetic diagnosis and haplotyping for congenital hyperinsulinism. Reprod Biomed Online 2011;22:72-9.

29. Grewal SS, Kahn JP, MacMillan ML, Ramsay NK, Wagner JE. Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. Blood 2004;103:1147-51.

30. Verlinsky Y. Ethics of preimplantation genetic diagnosis. Reprod Biomed Online 2007;14 Suppl 1:102-3.

31. Poulton J, Chiaratti MR, Meirelles FV, Kennedy S, Wells D, Holt J. Transmission of mitochondrial DNA diseases and ways to prevent them. PLoS Genet 2010;6:e1001066.

32. Bredenoord AL, Dondorp W, Pennings G, De Wert G. Avoiding transgenerational risks of mitochondrial DNA disorders: a morally acceptable reason for sex selection? Hum Reprod 2010;25:1354-60.

33. Zheng YM, Wang N, Li L, Jin F. Whole genome amplification in preimplantation genetic diagnosis. J Zhejiang Univ Sci B 2011;12:1-11.

34. Hellani A, Coskun S, Tbakhi A, Al-Hassan S. Clinical application of multiple displacement amplification in preimplantation genetic diagnosis. Reprod Biomed Online 2005;10:376-80.

35. Bosso M, Al-Mulla F. Whole genome amplification of DNA extracted from FFPE tissues. Methods Mol Biol 2011;724:161-80.

36. Geigl JB, Speicher MR. Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nat Protoc 2007;2:3173-84.

37. Franssen MT, Musters AM, van der Veen F, Leschot NJ, Bossuyt PM, et al. Reproductive outcome after PGD in couples with recurrent miscarriage carrying a structural chromosome abnormality: a systematic review. Hum Reprod Update 2011;17:467-75.

38. Scriven PN, Handyside AH, Ogilvie CM. Chromosome translocations: segregation modes and strategies for preimplantation genetic diagnosis. Prenat Diagn 1998;18:1437-49.

39. Lim CK, Cho JW, Song IO, Kang IS, Yoon YD, Jun JH. Estimation of chromosomal imbalances in preimplantation embryos from preimplantation genetic diagnosis cycles of reciprocal transloca-
51. Munné S, Chen S, Fischer J, Colls P, Zheng X, Stevens J, et al. Preimplantation genetic diagnosis reduces pregnancy loss in women aged 35 years and older with a history of recurrent miscarriages. Fertil Steril 2005;84:331-5.

52. Munné S, Howles CM, Wells D. The role of preimplantation genetic diagnosis in diagnosing embryo aneuploidy. Curr Opin Obstet Gynecol 2009;21:442-9.

53. Mastenbroek S, Twisk M, van der Veen F, Repping S. Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. Hum Reprod Update 2011;17:454-66.

54. Musters AM, Repping S, Korevaar JC, Mastenbroek S, Limpens J, van der Veen F, et al. Pregnancy outcome after preimplantation genetic screening or natural conception in couples with unexplained recurrent miscarriage: a systematic review of the best available evidence. Fertil Steril 2011;95:2153-7.e3.

55. Donoso P, Staessen C, Fauser BC, Devroey P. Current value of preimplantation genetic aneuploidy screening in IVF. Hum Reprod Update 2007;13:15-25.

56. Fragouli E, Katz-Jaffe M, Alfarawati S, Stevens J, Colls P, Goodall NN, et al. Comprehensive chromosome screening of polar bodies and blastocysts from couples experiencing repeated implantation failure. Fertil Steril 2010;94:875-87.

57. Fragouli E, Lenzi M, Ross R, Katz-Jaffe M, Schoolcraft WB, Wells D. Comprehensive molecular cytogenetic analysis of the human blastocyst stage. Hum Reprod 2008;23:2596-608.

58. Liebaers I, Desmyttere S, Verpoest W, De Rycke M, Staessen C, Sermon K, et al. Report on a consecutive series of 581 children born after blastomere biopsy for preimplantation genetic diagnosis. Hum Reprod 2010;25:275-82.

59. Nekkebroeck J, Bonduelle M, Desmyttere S, Van den Broeck W, Ponjaert-Kristoffersen I. Mental and psychomotor development of 2-year-old children born after preimplantation genetic diagnosis/screening. Hum Reprod 2008;23:1560-6.